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A Myristoyl/Phosphotyrosine Switch Regulates c-Abl
phosphorylation-dependent conformational changes inOliver Hantschel,1,5 Bhushan Nagar,3,5
Sebastian Guettler,1 Jana Kretzschmar,1 the activation loop, located between the two lobes that
form the kinase domain, these mechanisms include theKarel Dorey,1,6 John Kuriyan,3,4,*
and Giulio Superti-Furga1,2,* alteration of the relative orientation and stiffness of the
two lobes relative to one another, the blockage of sub-1Developmental Biology Programme
European Molecular Biology Laboratory strate or ATP access, and changes in subcellular local-
ization and degradation (Cox et al., 1994; Huse and Kuri-2 Cellzome AG
Meyerhofstrasse 1 yan, 2002; Hubbard, 2002).
Among the best understood of the protein kinases69117 Heidelberg
Germany in terms of their autoinhibitory mechanism are the Src
kinases, a prominent family of nonreceptor tyrosine ki-3 Howard Hughes Medical Institute
Department of Molecular and Cell Biology nases (Hubbard, 1999; Blume-Jensen and Hunter, 2001).
Src kinases are tightly regulated by phosphorylation atDepartment of Chemistry
University of California, Berkeley a conserved tyrosine in the C-terminal tail of the mole-
cule. C-terminal phosphorylation causes the intramolec-4 Physical Biosciences Division
Lawrence Berkeley National Lab ular engagement of the enzyme’s own SH2 domain with
the phosphorylated tail (Sicheri et al., 1997; Xu et al.,Berkeley, California 94720
1997; Williams et al., 1997). This results in the binding
of the SH3 domain to a region linking the SH2 and kinase
domains (SH2-kinase linker), a dislocation of the C-helixSummary
in the kinase domain, a closure of the small N-terminal
and large C-terminal kinase lobes, and an unproductiveThe c-Abl tyrosine kinase is inhibited by mechanisms
conformation of the activation loop. These changes arethat are poorly understood. Disruption of these mech-
incompatible with high catalytic activity (Gonfloni et al.,anisms in the Bcr-Abl oncoprotein leads to several
1997, 1999).forms of human leukemia. We found that like Src ki-
Activation of the Src kinases can occur by interferingnases, c-Abl 1b is activated by phosphotyrosine li-
with this inactive conformation through binding of li-gands. Ligand-activated c-Abl is particularly sensitive
gands to the SH3 domain, competing with high-affinityto the anti-cancer drug STI-571/Gleevec/imatinib (STI-
phosphotyrosine ligands for the SH2 domain, and phos-571). The SH2 domain-phosphorylated tail interaction
phorylating the activation loop tyrosine (Moarefi et al.,in Src kinases is functionally replaced in c-Abl by an
1997; Gonfloni et al., 2000; Porter et al., 2000; Liu et al.,intramolecular engagement of the N-terminal myris-
1993; Roussel et al., 1991). These features make the Srctoyl modification with the kinase domain. Functional
kinases efficient at integrating various signals, allowingstudies coupled with structural analysis define a myri-
them to act as protein-protein interaction adapters andstoyl/phosphotyrosine switch in c-Abl that regulates
regulators.docking and accessibility of the SH2 domain. This
The human ABL1 and ABL2 genes encode two tyro-mechanism offers an explanation for the observed cel-
sine kinases, c-Abl and Arg, which are closely relatedlular activation of c-Abl by tyrosine-phosphorylated
to the Src kinases (Van Etten, 1999; Superti-Furga andproteins, the intracellular mobility of c-Abl, and it pro-
Courtneidge, 1995; Pendergast, 2002), but display somevides new insights into the mechanism of action of
critical differences: c-Abl and Arg are twice as largeSTI-571.
as the Src kinases because they contain an additional
C-terminal region, encoded by a single exon, which con-Introduction
tains nuclear import and export signals as well as several
docking sites for cellular proteins, including signalingCellular regulation and signal transduction often result
adapters and actin. c-Abl is expressed in two alterna-in the modulation of the activity of protein kinases, the
tively spliced forms, 1a and 1b, which differ in the lengthsagents of most of the ensuing changes (Brasher and
of their first exon regions (Smith and Mayer, 2002). TheVan Etten, 2000; Schlessinger, 2000; Hubbard and Till,
1b form is 19 residues longer, contains a myristoylation2000). Thus, different forms of the 518 protein kinases
signal, and seems to be expressed in all cell types (Ren-encoded by the human genome (Manning et al., 2002)
shaw et al., 1988).have adopted a great number of variations of a limited
The cellular activity of c-Abl is normally low (Pender-set of fundamental regulatory options, usually involving
gast, 2002; Smith and Mayer, 2002; Van Etten, 1999).conformational changes and differential alignment of
Mutagenesis studies based on the structure of the Srccatalytic residues. In addition to regulation through
kinases led to the proposal that Abl and Arg are regu-
lated by essentially the same set of intramolecular inter-
*Correspondence: superti@embl-heidelberg.de (G.S.-F.), kuriyan@ actions that govern the Src kinases (Barila´ and Superti-
uclink.berkeley.edu (J.K.)
Furga, 1998; Pluk et al., 2002). What is achieved by5 These authors contributed equally to this work.
engagement of the tail with the SH2 domain in Src ki-6 Present address: Cancer Research UK, London Research Institute,
44 Lincoln’s Inn Fields, WC2A 3PX London, United Kingdom. nases may in c-Abl be replaced by interaction of a
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unique N-terminal “cap” with the rest of the molecule A Functional Requirement for the Myristoyl
Binding Pocket(Pluk et al., 2002; Sawyers, 2002; Hubbard, 2002).
Although the architecture of the inactive form was not Purification of the minimal c-Abl 1b construct that is
autoregulated (residues 1–531) from insect cells unex-revealed by these studies, they demonstrated that the
minimal region required for c-Abl regulation includes pectedly produced extremely soluble myristoylated pro-
tein. This suggested that the myristoyl modificationonly the first half of the molecule, comprising the cap
and the SH3, SH2, and kinase domains. This pointed to might be sequestered within the rest of the protein. We
performed isothermal titration calorimetry (ITC), usinga new strategy for the structural analysis of the minimal
elements of c-Abl regulation, focused on the first 530 the isolated Abl kinase domain (Nagar et al., 2002;
Schindler et al., 2000) and a myristoylated peptide corre-residues of the protein. In the process of purifying this
autoinhibited smaller form of c-Abl, we noticed that the sponding to the residues of the very N terminus of c-Abl
1b. We added STI-571 to the kinase domain since thisprotein was fully myristoylated, as expected, but ex-
tremely soluble. The ensuing structure-function analysis is thought to improve its stability. This peptide bound
to the kinase domain of c-Abl with an affinity of 2 M,resulted in the determination of three crystal structures
of Abl (Nagar et al., 2003 [this issue of Cell]) and in the while a peptide with the same sequence but lacking the
myristoyl group did not bind (Figure 2A and data notdefinition of a myristoyl and SH2-domain dependent
switch that allows c-Abl to be regulated, like Src- shown). This result strongly indicated that the kinase
domain of c-Abl has a binding site for the myristoylkinases, by phosphotyrosine-containing ligands.
group and led us to determine the crystal structure of
the Abl kinase domain in complex with a myristoylatedResults
peptide. The crystal structure as well as two structures
of larger c-Abl constructs showed the myristoyl groupMyristoylation Is Critical for c-Abl Regulation
bound in a deep hydrophobic pocket at the base of thec-Abl has been shown to be myristoylated, as predicted
kinase domain (Figures 2B and 2C; Nagar et al., 2003).by its primary structure, on the glycine residue at posi-
Four  helices form a deep cleft covered by the I-tion 2 (Jackson and Baltimore, 1989; Resh 1999). We
helix, which is positioned as a lid on top of the pocketpurified recombinant variants of the minimal regulated
(Figure 2C). In order to test whether exclusion of theform of c-Abl 1b from insect cells for crystallization trials
myristoyl group from this pocket in the kinase domainand tested their activity. Surprisingly, Abl forms in which
led to a similar level of activation as does the preventionthe glycine at position 2 had been mutated to alanine
of myristoylation, we mutated residues located within(G2A mutation) displayed dramatically higher activity
this pocket, introducing either bulkier side chains orthan wild-type c-Abl and was not myristoylated, as con-
polar residues into its hydrophobic environment (Fig-firmed by mass spectrometry (data not shown).
ure 2C).Also, expression of full-length c-Abl bearing the G2A
Forms of full-length c-Abl 1b bearing the A356N andmutation in HEK 293 cells resulted in high cellular phos-
V525D mutations were highly active, whereas the I521D,photyrosine levels. The Abl G2A protein was strongly
A452L, and F516N mutants were only slightly more ac-phosphorylated, in contrast to c-Abl wild-type (Figures
tive than c-Abl (Figure 2D). While none of the single point1A and 1B), presumably by autophosphorylation
mutations resulted in an activity comparable to that of(Brasher and Van Etten, 2000; Dorey et al., 2001). Abl
the G2A form, deletion of the entire I-helix (E517-G2A also displayed high in vitro tyrosine kinase activity
K527) led to an activation comparable to that seen forwith either GST-Crk or an optimal peptide as substrate
the G2A form lacking the myristoyl group.(Zhou et al., 1995; data not shown and see below). The
activity of Abl G2A was comparable to that of Abl PP,
a deregulated form in which two prolines in the SH2- Deregulation of Abl G2A Is Not Due
to Changes in Localizationkinase linker are mutated (P242E/P249E) (Barila´ and Su-
perti-Furga, 1998). Combination of the G2A and the PP N-myristoylation is often important in targeting proteins
to membranes (Resh, 1999). In order to test whether themutation (Abl G2A/PP) resulted in a form of the kinase
that was even more active than forms of c-Abl containing high activity observed for the G2A mutant is due to
altered subcellular localization we performed confocaleither of the individual mutations (Figure 1B). These re-
sults suggested an unexpected involvement of the myri- immunofluorescence microscopy with transfected
VERO monkey cells, which are particularly well-suitedstoyl modification in c-Abl regulation.
Abl PP and Abl G2A displayed very similar affinities for microscopy due to their large size and flat shape.
Under the settings used, endogenous c-Abl could hardlyfor the substrate (KM of 16 M and 13 M, respectively)
and similar maximum velocities (vmax 7.4 pmol/min and be detected (data not shown). All four forms of trans-
fected c-Abl (c-Abl, Abl PP, Abl G2A, and Abl G2A/6.5 pmol/min, respectively, Figure 1C). Thus, mutation
of the myristoyl acceptor site activated c-Abl as much PP) were abundant in the cytoplasm, and only a minor
fraction was found in the nucleus (Figure 3A, left). Co-as the mutation in the SH2-kinase linker (Abl PP), which
was previously the most activating of the c-Abl muta- staining of the cells for F-actin suggested that the promi-
nent surface signal of Abl observed in all cells was due totions. c-Abl, in contrast, showed a higher KM (95 M)
and lower vmax (3.8 pmol/min). Interestingly, the G2A/PP colocalization of Abl with the cortical actin cytoskeleton
(Figure 3A, right two panels; Van Etten et al., 1994). Ablmutant protein had a lower KM (9 M) than Abl PP or
Abl G2A and a higher vmax (8.7 pmol/min), showing the G2A was localized similarly to c-Abl, as were Abl PP
and Abl G2A/PP. Similar results were obtained whensynergism between SH3 docking and the effect of the
myristoyl group. using HeLa and HEK 293 cells (data not shown).
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Figure 1. Myristoylation Is Critical for c-Abl Regulation
(A) HEK 293 cells were transiently transfected with the indicated SV40-driven Abl expression constructs. Cells were lysed 40 hr after transfection
and total protein extracts analyzed by anti-Abl and anti-phosphotyrosine immunoblotting.
(B) Abl immunoprecipitates were probed with anti-Abl and anti-phosphotyrosine antibodies (lower panels) and assayed for catalytic activity
by in vitro kinase assays using an optimal substrate peptide. The histograph shows the catalytic activity (mean with S.D. of three experiments
done in duplicate) of the Abl constructs relative to c-Abl and corrected for endogenous c-Abl levels.
(C) Immunoprecipitated Abl proteins were assayed for catalytic activity in the presence of 100 M ATP and the indicated concentrations of
an optimal substrate peptide. Specific activity was calculated and plotted over the substrate concentration (Michaelis-Menten graph, top).
The graph shows the mean with S.D. of two experiments done in duplicate. The double-reciprocal plot (Lineweaver-Burk plot) was used to
calculate Km and vmax.
In order to get more quantitative insight into the sub- 7–10 to alanine) and cap6 (amino acids 70–73 to alanine)
are deregulated (Pluk et al., 2002). We mutated each ofcellular localization of c-Abl, HEK 293 cells expressing
the residues in cap1 and cap6 individually. Within thethe same forms of Abl as used for microscopy were
cap1 region, only the K7A mutant was activating (datafractionated into extracts enriched in nuclear, cytosolic,
not shown). Since positively charged residues at posi-or membrane proteins by differential velocity centrifuga-
tion 7 are necessary for N-myristoylation, the K7A muta-tion. Equivalent amounts of total protein were used for
tion may be impairing myristoylation of c-Abl. On thedetection of Abl in immunoblots (Figure 3B, top). Parallel
other hand, three single point mutations in the cap6immunodetection of nuclear (RCC1), cytosolic (-actin),
region (E71A, N72A, and L73A) resulted in a moderateand membrane (presenilin-1) proteins confirmed the pu-
increase in activity and one, K70A, was almost as activerity of the fractions (Figure 3B, bottom). In all cases, the
as Abl PP (Figure 4B).ratio of the total amount of Abl protein to the amount
An alignment of the cap regions of c-Abl 1b and c-Ablof Abl found in a particular fraction was the same for
1a (Figure 4A) prompted us to speculate that stretchesthe wild-type and mutant proteins. These observations
of residues between the conserved parts of the twosupport the view that the observed dramatic increase
alternative spliceforms (regions L1 and L2 in c-Abl 1b)in c-Abl activity upon removal of the myristoyl group
could loop out from a minimal link between the SH3was not due to a different localization of the bulk of the
domain and the myristoyl binding site and, therefore,protein.
be dispensable for autoinhibition. Indeed, Abl forms with
the L1, L2, L3, L4, or L5 regions deleted did not show
Proper Regulation of c-Abl Forms Containing significantly higher catalytic activity or levels of auto-
a Shortened N-Terminal Cap phosphorylation compared to c-Abl (data not shown).
The importance of myristoylation in the regulation of While even larger deletions of up to 45 amino acids
c-Abl raised the question as to whether the previously (L1-L5) did not lead to any increase in c-Abl activity,
analyzed cap region mainly serves as an unstructured a deletion of 54 residues (L1-L6) activated the kinase
and nonspecific bridge between the myristoyl group and (Figure 4D). The form of c-Abl with the largest deletion
the base of the kinase domain (Pluk et al., 2002). To in the cap and still properly regulated (L1-L5) was still
identify the minimal requirements for cap function, we dependent on myristoylation, as shown by the strong
introduced a series of point mutations and deletions increase in activity that results when the G2A mutation
into the region (Figure 4A). Previous results have shown is combined with this deletion (G2A/L1-L5, Figure 4D).
Interestingly, an increase in kinase activity was also seenthat two mutant forms of c-Abl 1b, cap1 (amino acids
Cell
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Figure 2. Myristoyl Binds a Hydrophobic Pocket in the Kinase Domain
(A) Isothermal titration calorimetry measuring binding of the purified Abl kinase domain to a myristoylated c-Abl 1b peptide (Myr-
GQQPGKVLGDQRRPSL). Top, raw data of the titration; bottom, integrated heats of injections, corrected for the heat of dilution.
(B) Backbone worm representation of the crytstal structure of myristoylated c-Abl 1b (residues 2–531) in complex with the inhibitor PD16.
The N-terminal myristoyl moiety is sequestered in a hydrophobic pocket in the large lobe of the kinase domain. Dotted lines indicate the
N-terminal cap (residues 2–79), which was disordered in the crystal. Some critical residues are labeled and shown as rod models. Tyr-412
specifies the activation loop phosphorylation site; Pro-242 and Pro-249 are mutated in Abl PP, and Arg-171 indicates the phosphotyrosine
binding site in the SH2 domain. The inhibitor PD16 and the N-terminal myristoyl are shown as CPK models.
(C) Closeup view of the myristoyl binding pocket in the large lobe of the kinase domain. The myristoyl is indicated in yellow, and key hydrophobic
residues that we have mutated are labeled and shown as rod models. The I-helix (residues E518–K527) is highlighted in red.
(D) The indicated Abl myristoylation pocket mutants were transiently expressed in HEK 293 cells. Anti-Abl immunoprecipitates were analyzed
by anti-Abl and anti-phosphotyrosine immunoblotting (bottom) and assayed for catalytic activity by in vitro kinase assays (top). The histograph
shows the fold activation of the indicated constructs compared to c-Abl (mean with S.D. of three experiments done in duplicate) and corrected
for endogenous c-Abl.
upon combining the G2A mutation with the K70A muta- In summary, only some 30 of the 80 residues linking
the myristoyl group to the SH3 domain appear to betion in the intact cap, suggesting that the cap does not
only function in presenting the myristoyl group (Fig- required for regulation. Within this minimal cap, an es-
sential element consists of the myristoyl group with itsure 4D).
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Figure 3. Subcellular Localization of Abl
(A) VERO cells were transiently transfected
with the indicated Abl expression constructs,
fixed 40 hr later, and immunostained with an
anti-Abl antibody (first panel). DNA was
stained with DAPI (second panel), and colo-
calization of Abl with actin was revealed using
phalloidin-rhodamine (third panel, actin;
fourth panel, merge Abl and actin). Images
show 1 m confocal sections in the mid-
nuclear planes.
(B) HEK 293 cells transiently transfected with
the indicated Abl constructs were fraction-
ated by differential velocity centrifugation.
Equal protein amounts were analyzed by im-
munoblotting using an anti-Abl antibody (top)
and antibodies against marker proteins for
the different subcellular compartments (bot-
tom; nuclear marker, RCC1; cytosolic marker,
-actin; membrane marker, presenilin-1).
P100 indicates the crude membrane fraction.
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Figure 4. Mutational Analysis of the N-Terminal Cap
(A) Alignment of the c-Abl type 1a and 1b N-terminal cap regions (exons 1 and 2). Residues K70–L73 are labeled with asterisks. Deletion
mutants are indicated.
(B–D) The indicated Abl cap mutants were transiently expressed in HEK 293 cells. Anti-Abl immunoprecipitates were analyzed by anti-Abl
and anti-phosphotyrosine immunoblotting (bottom) and assayed for catalytic activity by in vitro kinase assays using an optimal substrate
peptide (top). The histograph shows the fold activation of the different constructs compared to c-Abl (mean with SD of two experiments done
in duplicate) and corrected for endogenous c-Abl.
corresponding recognition motif for the N-Myristoyl- either of the two phosphopeptides (Figure 5A). Treatment
of wild-type c-Abl with the mutated control peptides hadtransferase (including Lys-7), and a second critical re-
gion comprises Lys-70, as well as Leu-73, proximal to no effect, suggesting phosphotyrosine-dependence of
the activation. Moreover, Abl R171L did not show anythe first  strand of the SH3 domain (Musacchio et al.,
1994). increase in kinase activity when treated with the phos-
phopeptides or the control peptides, demonstrating that
the activation requires a functional SH2-domain.
Activation by Phosphotyrosine Ligands This finding is explained by the crystal structures of
During the course of our investigations, we discovered regulated c-Abl, in which the SH2 domain packs against
that phosphopeptides are capable of activating c-Abl. the kinase domain in a way that partly occludes the
This finding could not be reconciled with currently ligand binding site. Specifically, although the phospho-
known mechanisms of c-Abl activation. To investigate tyrosine binding site of the SH2 domain is largely acces-
this phenomenon systematically, we treated c-Abl with sible, the kinase domain impairs binding by masking the
phosphopeptides derived from two c-Abl substrates binding sites for the residues immediately upstream of
known to bind the Abl SH2 domain (Barila´ et al., 2000; the phosphotyrosine (Nagar et al., 2003).
Zhu et al., 1994). As controls, we used peptides of the To evaluate the accessibility of the SH2 domain in
same sequence in which the phosphotyrosine was re- regulated c-Abl compared to active forms (Abl PP and
placed by a phenylalanine as well as an Abl form bearing Abl G2A), we determined the affinities of phosphopep-
a point mutation in the SH2 phosphotyrosine binding tide ligands for the SH2 domain by isothermal titration
site (Abl R171L, FLVR motif), which renders the SH2 calorimetry (ITC). c-Abl wild-type displayed a higher KD
domain incompetent for binding phosphotyrosine than the active forms Abl PP and Abl G2A. We also
detected lower binding stoichiometry for the wild-type(Mayer et al., 1992).
We observed a concentration-dependent increase in protein compared to its active counterparts (Table 1 and
data not shown). These observations indicated that thec-Abl activity when the wild-type protein is treated with
A Myristoyl/Phosphotyrosine Switch Regulates c-Abl
851
Figure 5. Positioning of the SH2 Domain and SH2 Domain-Dependent Regulation of c-Abl
(A) Immunoprecipitated c-Abl or Abl R171L was preincubated with the indicated concentrations of either phosphopeptide (pY) or a control
peptide (F). Abl catalytic activity was determined using an optimal substrate peptide. The results were normalized for the reaction in the
absence of phosphopeptide or control peptide, and relative Abl activity was calculated. The graph shows the mean with S.D. of three
independent experiments done in duplicate or triplicate for the Jun peptide (top) and the mean with S.D. of two independent experiments
done in duplicate for the EGFR peptide (bottom).
(B) Backbone worm representation of regulated c-Abl. The structure of the Abl kinase domain with an unoccupied myristoyl binding pocket
(PDB entry 1M52; Nagar et al., 2002) is superimposed onto the regulated c-Abl structure. The I-helix of the myristoyl-free Abl kinase domain,
shown in orange, clashes with the SH2 domain. Key residues in the SH2 domain are shown as rod models.
(C) Backbone worm representation of the SH2-kinase domain interface in c-Abl. Key residues that we have mutated are labeled and shown
as rod models.
(D) The SH2-kinase domain interface mutants were transiently expressed in HEK 293 cells. Anti-Abl immunoprecipitates were analyzed by
anti-Abl and anti-phosphotyrosine immunoblotting (bottom) and assayed for catalytic activity by in vitro kinase assays using an optimal
substrate peptide (top). The histograph shows the fold activation of the different constructs compared to c-Abl (mean with S.D. of two
experiments done in duplicate) and corrected for endogenous c-Abl.
phosphotyrosine binding sites of active Abl forms are 112/6/845/DC1). However, Abl proteins mutated in Glu-
157, Tyr-158, Val-357, or Tyr-361 showed an intermedi-more accessible than the ones of the wild-type protein.
ate to strong increase in phosphorylation of cellular pro-
teins on tyrosine (data not shown), autophosphorylation,The SH2-Kinase Domain Interface Is Critical
and kinase activity when mutated (Figure 5D).for Autoinhibition
These observations demonstrated that the interfaceThe crystal structures of regulated c-Abl show that
between the SH2 and kinase domains is involved inthe SH2 domain packs tightly against the large lobe
regulating c-Abl and that Tyr-158 in particular may beof the kinase domain. The I-helix at the C terminus of
a key determinant for proper positioning of the SH2the kinase domain without bound myristoyl group (Nagar
domain.et al., 2002, Schindler et al., 2000) projects into the space
occupied by the SH2 domain in the assembled structure,
effectively preventing SH2 domain docking (Figure 5B). A Conserved Snap-Lock Mechanism Involving
the SH3/2 ConnectorThe comparison suggests a myristoyl switch mecha-
nism in which binding of the myristoyl group causes the Molecular dynamics simulations indicated that the SH3
and SH2 domains in Src family kinases are tightly cou-I-helix to bend and position the I-helix as a lid onto
the myristoyl binding pocket, thereby rendering the pled via a rigid connector and that the connector func-
tions as an inducible snap-lock in Src kinases (Youngdocking site accessible for the SH2 domain. We tested
this hypothesis by mutating residues at the SH2-kinase et al. 2001). In support of this model, replacement of
connector residues with glycines leads to a strong acti-domain interface (Figure 5C). Several mutations showed
only minor effects on c-Abl activity (see Supplemental vation of c-Src (Young et al., 2001).
Superimposition of the crystal structures of regulatedTable S1 online at http://www.cell.com/cgi/content/full/
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tide in the absence of ATP. This activated form of c-AblTable 1. Isothermal Titration Calorimetry (ITC) of Different Abl
showed a significantly lower IC50 for STI-571 (150 nM)Mutants with a Phosphopeptide
than c-Abl. On the other hand, Abl PP, which is strongly
c-Abl1–531 Construct KD/M phophorylated on Tyr-412 (Dorey et al., 2001), displayed
Abl D382N 19.1 a higher IC50 (800 nM) than c-Abl wild-type (Figure 6D).
Abl D382N/PP 7.2 Taken together, these data indicated that the confor-
Abl D382N/G2A 7.7 mational state of c-Abl had an impact on the ability of
Recombinant proteins were expressed in Sf9 cells and purified in STI-571 to inhibit catalytic activity, as previously sug-
the presence of PD16 (Nagar et al., 2003). Isothermal titration calo- gested (Roumiantsev et al., 2002). The inhibitory SH3/2
rimetry (ITC) was performed using a VP-ITC machine (MicroCal). clamp appears to counteract binding of STI-571 to the
Abl:PD16 complexes and peptide sample (GNPVpYENV; Zhu et al., ATP binding site, presumably by restraining movements
1994) were transferred to a buffer containing 20 mM Tris/HCl (pH
of the kinase domain lobes relative to each other in the8.0), 150 mM NaCl, and 5 mM DTT. Titrations were performed at
regulated conformation, making it more difficult for the25C by injecting 25–30 consecutive aliquots of 10 l of peptide
relatively large STI-571 to enter the kinase domain.solution (1 mM) into the ITC cell containing Abl:PD16 complex (100
M). The thermodynamic parameters of the reaction were deter-
mined by fitting the corrected data to a bimolecular interaction Discussion
model.
Important common themes have emerged from the anal-
ysis of the regulatory mechanisms of protein kinases,
suggesting that kinases that are closely related mightc-Abl and c-Src showed a remarkable overlap of the
share common mechanisms of action (Huse and Kuri-SH3-SH2 domain clamps, including their SH3/2 connec-
yan, 2002; Schlessinger, 2000; Hubbard, 2002; Hubbardtors (Figure 6A). Moreover, Ser-140 in the connector of
and Till, 2000; Taylor and Radzio-Andzelm, 1997; Blume-c-Abl has been identified as a critical residue in a random
Jensen and Hunter, 2001). Recent work, as well as thescreen for c-Abl activating mutants (Brasher et al., 2001).
evidence provided by this and the accompanying paperWe tested the effect of a triple glycine mutation (S140G/
(Nagar et al., 2003) on the structure of regulated c-Abl,L141G/E142G) aimed at disrupting the structural rigidity
shows that the Src and Abl kinases are very similar inof the connector (Figure 6B). The triple glycine mutant
their internal control mechanisms (Barila´ and Superti-was indeed autophosphorylated, showed high tyrosine
Furga, 1998; Plattner et al., 1999; Brasher et al., 2001;kinase activity in vitro and in vivo, and was stronger in
Pluk et al., 2002; Huse and Kuriyan, 2002). Like the Srcactivity compared to the S140I mutant used as a control
kinases, c-Abl and its paralogue Arg (S.G., O.H. and(Figure 6C; Brasher et al., 2001).
G.S.F., unpublished data), are negatively regulated byThese results suggested that the role of the SH3/2
an intramolecular SH3 domain-mediated interactionconnector in the autoregulatory mechanism is con-
“sandwich” involving the linker and the kinase domainserved between c-Src and c-Abl. It remains to be deter-
and can be activated by phosphorylation of their activa-mined how uncoupling of the two domains is regulated
tion loop (Plattner et al., 1999; Brasher and Van Etten,in wild-type c-Abl, because the molecular uncoupling
2000; Dorey et al., 2001; Furstoss et al., 2002). Mostswitch equivalent to the release of the tail phosphotyro-
surprisingly, c-Abl is also activated by phosphotyrosinesine in c-Src is not evident.
ligands. The implication is that the Src kinases and Abl/
Arg are essentially built to execute a core function of
Ligand-Activated c-Abl Has Heightened transducing protein-protein interaction signals into a
Sensitivity to STI-571 phosphorylation signal that generates further protein-
STI-571 has been demonstrated to inhibit Bcr-Abl and protein interactions. Conversely, they engage in protein-
to block c-Abl-dependent actin microspike formation protein interactions in response to phosphorylation
in cells spreading on fibronectin (Druker et al., 1996; events that alter the conformation of their kinase domain
Woodring et al., 2002). Crystal structures of Abl bound (Gonfloni et al., 2000; Porter et al., 2000).
to this inhibitor have been determined (Nagar et al., Burial of the myristoyl group within the kinase domain
2002, 2003). Whether STI-571 can inhibit c-Abl activity may explain why c-Abl is able to shuttle between the
is not known because no experimental protocol to pre- nucleus and the cytoplasm, depending on environmen-
serve c-Abl regulation in vitro was available until recently tal cues, in a manner that had been difficult to reconcile
(Plattner et al., 1999; Pluk et al., 2002). STI-571 only with constitutive membrane association (Taagepera et
binds efficiently to the Abl kinase domain when the acti- al., 1998; Van Etten, 1999). In general, myristoylation is
vation loop tyrosine (Tyr-412) is not phosphorylated not necessarily coincident with membrane association,
(Schindler et al., 2000; Nagar et al., 2002). This conforma- as there are several myristoylated proteins that are solu-
tion is associated with low catalytic activity (Dorey et ble (Resh, 1999; Taniguchi, 1999) and the myristoyl
al., 2001). group is insufficient to stably anchor proteins to mem-
We determined the catalytic activity of immunoprecip- branes on its own (Resh, 1994). A different matter alto-
itated c-Abl wild-type and Abl PP in the presence of gether is the myristoylation-dependent transforming ac-
various concentrations of STI-571. c-Abl wild-type tivity of deregulated forms of c-Abl, like v-Abl. In these
showed an inhibition curve with an IC50 of 400 nM for cases, activation of membrane bound GTPases, re-
STI-571. To obtain a form of c-Abl that is released from sulting in activation of MAP kinase pathways, appears
the inhibitory restraints of the SH3 and SH2 domains to be a prerequisite (Daley et al., 1992; McWhirter et al.,
but is not already phosphorylated on Tyr-412 like Abl 1993; Raitano et al., 1997; Feller et al., 1994; Van Etten,
1999).PP, we activated c-Abl allosterically with a phosphopep-
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Figure 6. Role of the SH3-SH2 Connector
and Inhibition by STI-571
(A) Superimposition of the SH3-SH2 regions
of regulated c-Src (red backbone worm; PDB
entry 2SRC) and c-Abl (green backbone
worm) in two different orientations. The right
panel shows a view that is rotated 45 coun-
terclockwise around the vertical axis.
(B) Closeup view of the SH3-SH2 connector
in regulated c-Abl. Residues that we have mu-
tated are labeled and shown as rod models.
(C) The connector mutants were transiently
expressed in HEK 293 cells. Anti-Abl immu-
noprecipitates were analyzed by anti-Abl and
anti-phosphotyrosine immunoblotting (bot-
tom) and assayed for catalytic activity by in
vitro kinase assays using an optimal sub-
strate peptide (top). The histograph shows
the fold activation of the different constructs
compared to c-Abl (mean with S.D. of two
experiments done in duplicate) and corrected
for endogenous c-Abl.
(D) c-Abl or Abl PP protein was immunopre-
cipitated (for the c-Abl and Abl PP control
reactions) or immunoprecipitated and acti-
vated with phosphopeptide (c-Abl activated).
STI-571 was added at the indicated concen-
trations. Catalytic activity was determined
and normalized for the reaction in the ab-
sence of STI-571. The graph shows the mean
with S.D. of three independent experiments
done in duplicate. The chemical structure of
the inhibitor is indicated.
A critical question left open concerns the active role like the Src kinases, by phosphotyrosine ligands. This
surprising finding offers an explanation for two phenom-of myristoylation in normal c-Abl function. Does the myr-
istoyl group ever leave the pocket? Are there dedicated ena that have remained unexplained: activation of c-Abl
by high concentration of substrates and dependenceproteins sequestering it? The alternatively spliced form
c-Abl 1a is 19 residues shorter and not myristoylated. on the SH2 domain for efficient phosphorylation by c-Abl
(Smith and Mayer, 2002). c-Abl substrates may initiallyBoth forms can independently rescue the defects
caused by c-Abl gene knockout (Hardin et al., 1996), be phosphorylated through the basal kinase activity of
c-Abl or other kinases and initiate a positive feedbacksuggesting that myristoylation does not have an irre-
placeable role in the cellular function of c-Abl. c-Abl loop involving SH2 domain-dependent activation of c-Abl
and resulting in facilitated substrate recruitment. Thisbearing the type 1a exon is equally well regulated in
vitro and in vivo when expressed in HEK 293 cells (O.H. may not only form the basis for our previous insights into
the nuclear tyrosine phosphorylation circuit involvingand G.S.F., unpublished data). The elements of Abl 1a
that replace the action of the myristoyl group in Abl 1a c-Abl, its substrate c-Jun, and JNK (Barila´ et al., 2000),
but may also account for findings involving activationremain to be determined.
The most dramatic effect of the interaction of the by Abl interactor 1, Nck, paxillin, Cbl, -PAK, Cables,
and possibly also p73, c-Crk, Ena (enabled), disabled,myristoyl group and the kinase domain appears to be
the gating effect on SH2 docking. Given the network and many other proteins (reviewed in Pendergast, 2002).
In addition to the proposed role for the SH2 domain inof SH2-kinase domain interactions and the snap-lock
mechanism of the SH3/SH2 clamp, c-Abl is activated, increasing the processivity of the enzyme (Smith and
Cell
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Figure 7. Schematic Representation of c-Abl Activation Modes
(A) Schematic representation of regulated c-Abl 1b (center). The domains and linkers are colored as in all other figures. Surrounding the
central figure, four potential activation mechanisms for c-Abl 1b and their concomitant potential domain rearrangements are shown: SH3
domain-dependent activation (upper left), SH2 domain-dependent activation (lower left), activation by phosphorylation on Tyr-412 (activation
loop) or Tyr-245 (SH2-kinase linker) (upper right), and activation by myristoyl displacement (lower right).
(B) Schematic representation of fully active c-Abl 1b.
Mayer, 2002), phosphotyrosine ligands can shift c-Abl proposed to be participating in c-Abl regulation, includ-
ing the cap, confer STI-571 resistance to Bcr-Abl (Azaminto an active conformation, preventing it from reassum-
ing the regulated, inhibited conformation. In agreement et al., 2003 [this issue of Cell]). Residual regulatory con-
straints must therefore be operational within Bcr-Ablwith this hypothesis, it has been reported that c-Abl
binds to receptor tyrosine kinases, such as EphB2 (Yu despite the lack of a myristoyl group and in competition
to the activation caused by BCR-driven dimerization.et al., 2001) and Trk (Yano et al., 2000), as well as to the
B cell receptor ancillary protein CD19 (Zipfel et al., 2000). The crystal structure of the myristoylated form of c-Abl
shows regions of electron density in the vicinity of theA model summarizing the different modes of c-Abl
activation is shown in Figure 7. Starting from the regu- SH3 domain N terminus likely to represent interaction
sites of the C-terminal part of the cap (functionally identi-lated conformation of the kinase, c-Abl could be acti-
vated by either SH3 or SH2 domain ligands, leading to fied Lys-70 and Leu-73, Figure 4A; Nagar et al., 2003).
The previously documented interaction of a GST-Capdisplacement of the inhibitory clamp from the backside
of the kinase domain. Myristoyl displacement by a yet fusion protein with the SH3-SH2 domain must mainly
occur in this region. Phosphotyrosine-ligand activatedunidentified class of fatty-acid binding proteins might
lead to a concomitant disruption of the SH2-kinase do- c-Abl, in which the conformational restraints conferred
by the SH3/SH2 clamp are not operational, is particularlymain interface. These mechanisms might lead to a fully
activated form of the kinase, which can be further stabi- sensitive to inhibition by STI-571. This suggests that
“breathing” of the N-terminal and C-terminal lobes is anlized, as well as initiated, by phosphorylation of the acti-
vation loop tyrosine Tyr-412 and/or Tyr-245 in the SH2- important parameter for the selectivity of protein kinase
inhibitors, which may need to be “swallowed.” Thesekinase linker (Plattner et al., 1999; Dorey et al., 2001;
Brasher and Van Etten, 2000). Once phosphorylated, observations offer a potential explanation for the relative
safety of STI-571 in treatment of leukemia patients.c-Abl can reassume its regulated state upon the action
of cellular phosphatases (Cong et al., 2000). Since the developmental effects of loss of function of
the ABL1 or/and ABL2 genes in the mouse are quiteWe have previously found that the cap region could
partly restore inhibition of a dimerization-defective form severe (Schwartzberg et al., 1991; Tybulewicz et al.,
1991; Koleske et al., 1998), one could have anticipatedof the Bcr-Abl fusion protein (Pluk et al., 2002). This
implies that regulatory constraints and activation modes toxicity problems through inhibition of the cellular form
of the enzyme.as described in the model of Figure 7 may be operational
within Bcr-Abl (Pluk et al., 2002; Sawyers, 2002). This The myristoyl pocket appears to be quite specific for
c-Abl and Arg as the corresponding space in Src kinasesview has now been prominently confirmed by an elegant
genetic analysis revealing that mutations in all surfaces is filled with bulky side chains. It is possible that the
A Myristoyl/Phosphotyrosine Switch Regulates c-Abl
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Drug Inhibition Assaymyristoyl binding pocket offers new opportunities for
c-Abl wild-type or Abl PP protein was immunoprecipitated fromBcr-Abl inhibitors since molecules that bind to it might
total cell extracts as described above. The immunoprecipitates werebe able to stabilize the inactive and assembled confor-
resuspended in kinase assay buffer (for the c-Abl wild-type and
mation of the enzyme. Abl PP control reactions) or kinase assay buffer containing 1 mM
phosphopeptide in order to activate c-Abl. STI-571 was added at
Experimental Procedures the indicated concentrations. The kinase assay was carried out
as described previously (Pluk et al., 2002). Each experiment was
DNA Constructs normalized for a reaction in the absence of STI-571, and relative
pSGT vector and pSGT-Abl constructs were previously described Abl activity was calculated.
(Barila´ and Superti-Furga, 1998). All point mutations and deletions
were obtained using the quick-change site-directed mutagenesis Acknowledgments
kit (Stratagene) and pSGT-Abl 1b as template. All mutations were
confirmed by sequencing. We would like to thank J.R. Engen for early insights into the SH2-
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